This announcement is a separate document:
毕马威华振会计师事务所（特殊普通合伙）关于北京昭衍新药研究中心股份有限公司2023年年报问询函中要求会计师答复的相关问题的回复
Response from KPMG Huazhen Certified Public Accountants (Special General Partnership) on the questions requested from accountants in the inquiry letter for the 2023 annual report of Beijing Zhaoyan New Drug Research Center Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.